Advanced Solid Tumors
Advanced Solid Tumors
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
20
Clinical Trials
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT05327946 / 1501-0001
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06596473 / BG-C477-101
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06598800 / BG-T187-101
An Investigational Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT05981703 / BGB-A317-26808-101
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT05471856 / BI1480-0001
Phase Ia, first in human open label, dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours
Learn More
Advanced Solid Tumors
Phase I/II
Enrolling
nct/study# NCT06697197 / BMS-CA236-0001
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.